Astria Therapeutics(ATXS.US)

Last Updated 19:00:00 ET
longbridge loading

20:10 ETAscletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes

prnewswire·
US
ATXS
0.00%
US
FBT
+2.14%
US
BBH
+0.96%
prnewswire·
US
ATXS
0.00%
US
FBT
+2.14%
US
BBH
+0.96%

Egetis Appoints Tiago Nunes as Chief Medical Officer

MorningStar·
US
ATXS
0.00%
US
NBSE.ESC
0.00%
MorningStar·
US
ATXS
0.00%
US
NBSE.ESC
0.00%

Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report

Tip Ranks·
US
ATXS
0.00%
Tip Ranks·
US
ATXS
0.00%

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board | COSM Stock News

StockTitan·
US
COSM
+0.64%
US
XHE
+2.17%
US
XLV
-0.13%
StockTitan·
US
COSM
+0.64%
US
XHE
+2.17%
US
XLV
-0.13%

Axtria releases U.S. Incentive Compensation Benchmarking Study 2026 to aid life sciences, enhancing performance.

Unusual Whales·
US
ATXS
0.00%
SH
CS精准医
+1.54%
Unusual Whales·
US
ATXS
0.00%
SH
CS精准医
+1.54%

Will BioCryst's ORLADEYO Hit The $1 Billion Sales Mark?

rttnews·
US
XLV
-0.13%
US
XBI
+3.88%
US
IHE
+0.84%
rttnews·
US
XLV
-0.13%
US
XBI
+3.88%
US
IHE
+0.84%
© 2026 Longbridge｜Disclaimer